NIH DRUG DISCOVERY AND DEVELOPMENT CONSULTING SERVICES
Department of Health and Human Services, National Institutes of Health | Published February 23, 2016 - Deadline May 15, 2016
This is a solicitation for commercial services prepared in accordance with the format in Subpart 12.2, as supplemented with additional information included in this notice. The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-87 effective April 6, 2016. This acquisition will be processed under FAR Part 12, Simplified Acquisition Procedures (SAP), Acquisition of Commercial Items, and is set aside 100% for small businesses. The Solicitation Number for this acquisition is HHS-NIH-NIDA-SSSA-RFP-16-46 and is being issued as a Request for Proposal (RFP). The North American Industry Classification System (NAICS) Code for this procurement is 541690 and the Small Business Size Standard is $15.0 million dollars.
The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives.
The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the National Institutes of Health (NIH), conducting research into the causes, treatment, and prevention of neurological disorders and stroke. The NINDS mission is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
The NIH Blueprint for Neuroscience Research, a consortium of 8 NIH Institutes and Centers that support neuroscience research, established the Blueprint Neurotherapeutics Network (BPN) as a pipeline between the typical endpoint of NIH-funded research and the beginning of industry drug development. The BPN provides neuroscience researchers with funding and access to a full range of industry-style drug development services and expertise. The program is intended for projects requiring medicinal chemistry optimization and contract research organization (CRO) support through phase I clinical testing. Each project is directed by a Lead Development Team (LDT) composed of the principal investigator (PI), industry consultants hired by NIH, and NIH staff. This team maps out a research strategy, including milestones, and oversees implementation by CROs. Bioactivity and efficacy studies are funded through an award to the PI; other research services are provided without cost to the PI through NIH contracts.
Each consulting contract will be specific to one or more areas of expertise as outlined in the attached Statement of Work, and will reflect the NIH time commitment needs for the specific areas of expertise.
Consultants hired under this requirement will not only make significant contributions to promising drug discovery and development projects that have been selected through a rigorous peer-review process, they will also help shape an innovative, high-profile program that may serve as a model for future NIH drug discovery efforts.
Contract consultants will be expected to provide feedback and guidance on programs and projects to the NIH and to BPN LDT members through conference calls and by email. Consultants may serve on an ad hoc basis or as members of LDTs. Consultants will be expected to offer input on project milestones, development strategy, study design, and data interpretation. Specific consulting responsibilities will depend on the expertise of the individual consultant and the needs of individual projects and programs.
The BPN currently has projects in the exploratory through preclinical safety stages. Some projects will proceed to the Investigational New Drug (IND) and clinical trial stages. Project continuation will depend on the achievement of project-specific milestones and portfolio management. Since 2011, fifteen projects have entered the BPN, and five projects remain active. New projects are reviewed twice per year and the highest scoring projects may be incorporated into the program.
STATEMENT OF OBJECTIVES
The NIH is seeking senior-level, industry-experienced drug discovery and development consultants with expertise in the following specific disciplines to provide leadership and technical guidance on drug discovery and development projects in the Blueprint for Neuroscience Research (BPN) and possibly other NIH drug discovery and development projects and programs:
• Bioactivity Assay• Drug Metabolism and Pharmacokinetics
STATEMENT OF WORK
Please see the attached statement of work for detailed requirements. PERIOD OF PERFORMANCE
Base Year - June 1, 2016 through May 31, 2017Option Period One - June 1, 2017 through May 31, 2018Option Period Two - June 1, 2018 through May 31, 2019Option Period Three - June 1, 2019 through May 31, 2020Option Period Four - June 1, 2020 through May 31, 2021
LEVEL OF EFFORT
The NIH estimates that it will require the following labor hours for each of the specific disciplines as follows:
1. Bioactivity Assay Year 1: Up to 800 hours Year 2: Up to 800 hours Year 3: Up to 800 hours Year 4: Up to 800 hours Year 5: Up to 800 hours
2. Drug Metabolism and Pharmacokinetics Year 1: Up to 800 hours Year 2: Up to 800 hours Year 3: Up to 800 hours Year 4: Up to 800 hours Year 5: Up to 800 hours
The following attachment is provided to assist you in preparing your proposal responding to this solicitation.
Attachment No. 1: Statement of Work
PAGE AND FORMATTING LIMITATIONS
The Technical Proposal shall not exceed 50 single-sided pages or 25 double-sided pages. This page limitation does not include the cover sheet, abstract, table of contents, personnel, facilities, equipment and resources, other considerations, schedule, other support, and cost information. Appendices shall not exceed a total of 30 single-sided pages or 15 double-sided pages. Pages in excess of the limitation will be deleted and will be neither read nor evaluated. Each page of the technical proposal must be numbered sequentially. Offerors are encouraged to limit the overall size of the technical proposal, inclusive of appendices, attachments, etc.
Type density and size must be 10 to 12 points. If constant spacing is used, 15 cpi (characters per inch) or fewer shall be used, whereas proportional spacing should provide an average of no more than 15 cpi. There must be no more than six lines of text within a vertical inch. Margins must be no less than ½ inch around, exclusive of headers and footers.
The proposal must be signed by an official authorized to bind your organization and must stipulate that it is predicated upon all the terms and conditions of this RFP. One original and three (3) copies of your proposal shall be submitted to:
National Institutes of HealthNational Institute on Drug AbuseStation Support Simplified Acquisition BranchAndriani Buck, Contract Specialist31 Center Drive, Suite 1B59Bethesda, MD 20892-7511.
Proposals will be typewritten, paginated, reproduced on letter size paper, printed/copied double-sided, on at least 30 percent post consumer fiber paper, as required by FAR 4.302(b), and will be legible in all required copies. To expedite the proposal evaluation, all documents required for responding to the RFQ should be placed in the following order:
I. COVER PAGEInclude RFP title, number, name of organization, DUNS No., identification of the proposal part, and indicate whether the proposal is an original or a copy. The solicitation number HHS-NIH-NIDA-SSSA-RFP-16-46 must be referenced on the cover page.
II. TECHNICAL PROPOSALIt is recommended that the technical proposal consist of a cover page, a table of contents, and the information requested in the Technical Proposal Instructions and as specified in SECTION J, List of Attachments.
Offers will be valid for 120 days unless a different period is specified by the offeror.
MANDATORY EVALUATION FACTORS
Mandatory Evaluation CriteriaThe solicitation contains the following mandatory qualification criteria specific to each discipline:
1. Bioactivity Assay Development• An advanced degree in a life science discipline is required. An advanced degree is defined as any postgraduate degree, doctorate or master's level including but not limited to a Ph.D., Pharm.D., M.D., M.S. • 10 years of experience in the pharmaceutical or other related industry is required• Experience working with multi-disciplinary drug development teams at a senior level in the pharmaceutical industry. A senior level position is generally at the highest level of an organization.• Experience with drug discovery and development for nervous system conditions is required.
2. Drug Metabolism and Pharmacokinetics• An advanced degree in a life/physical science discipline is required.• 10 years of experience in pharmacokinetics and drug metabolism of small molecules.• Experience providing DMPK project leadership in support of small molecule drug discovery programs and/or experience providing DMPK leadership to development teams. • Experience with drug discovery and development for nervous system conditions is required.
The mandatory qualification criterion establishes conditions that must be met at the time of receipt of Technical Proposals by the Contracting Officer in order for your proposal to be considered any further for award.
TECHNICAL EVALUATION ELEMENTS
The evaluation factors are used by the technical evaluation committee when reviewing the technical proposals. Offerors proposals will be evaluated on the demonstrated experience and understanding of the project in relation to the specifications outlined in the solicitation and the statement of work.The acceptability of the technical portion of each contract proposal will be evaluated by a technical review committee. The committee will evaluate each proposal in strict conformity with the evaluation factors of the RFP, utilizing point scores and written critiques. The committee may suggest that the Contracting Officer request clarifying information from an offeror.
The Government reserves the right to award a contract without discussions if the Contracting Officer determines that the initial prices are fair and reasonable and that discussions are not necessary. If award will be made without conducting discussions, offerors may be given the opportunity to clarify certain aspects of their proposal (e.g., the relevance of an offeror's past performance information and adverse past performance information to which the offeror has not previously had an opportunity to respond) or to resolve minor or clerical errors.
The process described in FAR 15.101-1 will be employed, which permits the Government to make tradeoffs among cost or price and non-cost factors and to consider award to other than the lowest price offeror or other than the highest technically rated offeror.
The NIDA reserves the right to make a single award, multiple awards, or no award at all to the RFP. In addition, the RFP may be amended or canceled as necessary to meet the NIDA requirements.
Proposals will be scored based on the following three (3) technical evaluation criteria.
Professional Experience in Drug Development -50 points
Offerors shall be evaluated based on hands-on and management experience in drug discovery and development projects, explicitly applicable to the corresponding discipline description listed in the statement of work.
Evaluations shall be based on demonstrated expertise and experience in executing and managing drug development tasks, particularly for nervous system conditions. Broad experience across the entire drug discovery and development process is especially desired.
Reviewers shall consider the Offerors' years of experience, breadth of expertise, and track record in drug development projects that go through to the clinic. Examples of measures of success include preparation of successful IND, CTA, NDA, and MA applications, as well as publications, patents, and work on drugs brought to market. In addition, experiences showing use of expertise to identify or anticipate problems early, overcome technical or regulatory difficulties, distill complex situations, or demonstrate strong risk-assessment ability to make wise use of limited resources shall be considered as signs of a strong track record in drug development.
Discipline specific experience requirements for Bioactivity Assay Development are as follows: • Demonstrated experience developing and implementing cell-based and biochemical assays for high throughput screening and safety screening• Demonstrated expertise in the application of assays in industrial pharmaceutical discovery and development; application of automated technologies and robotics relevant to pharmaceutical assays; and application of a diverse range of cellular techniques in pharmaceutical assays
Education and Qualifications in Drug Development - 30 points
Offerors shall be evaluated for a combination of advanced education, board certifications, and other advanced expertise explicitly applicable to the corresponding discipline description listed in the statement of work. Evaluations shall be based on the Offerors' in-depth understanding of the drug development process, including regulatory procedures and guidelines where relevant, especially in small molecule drug development for CNS indications.
Experience with Collaborative Teams - 20 points
Offerors shall be evaluated based on previous experience working with multi-disciplinary teams, especially teams with members from outside organizations and members at various management levels. Experiences such as team leadership, consulting, or service on strategic and advisory boards shall be considered as illustrations of collaborative work.
Total Possible Points - 100
The Government will evaluate the Offerors on past performance based on the information provided in the proposal and the Government reserves the right to contact the parties provided as references in the Offerors proposal. In addition the Government may evaluate the Offeror based on information obtained from other sources known to the Government as to past performance of the Offeror.
PAST PERFORMANCE FACTOR
The Government may evaluate the offeror's past performance based on information obtained from references provided by the offeror, other relevant past performance information obtained from other sources known to the Government, and any information supplied by the offeror concerning problems encountered on the identified contracts and corrective action taken.
The Government will assess the relative risks associated with each offeror. Performance risks are those associated with an offeror's likelihood of success in performing the acquisition requirements as indicated by that offeror's record of past performance.
The Government will consider the currency and relevance of the information, source of the information, context of the data, and general trends in the offeror's performance.
The lack of relevant a performance record may result in an unknown performance risk assessment, which will neither be used to the advantage nor disadvantage of the offeror.
AWARD CRITERIAThe major evaluation factors for this solicitation include technical (which encompasses experience and past performance factors) and cost/price factors. Although technical factors are of paramount consideration in the award of the contract, cost/price is also important to the overall contract award decision. All evaluation factors other than cost or price, when combined, are significantly more important than cost/price. The Government intends to make an award(s) to that offeror whose proposal provides the best overall value to the Government.
The evaluation will be based on the demonstrated capabilities of the prospective Contractors in relation to the needs of the project as set forth in the RFP. The merits of each proposal will be evaluated carefully. Each proposal must document the feasibility of successful implementation of the requirements of the RFP. Offerors must submit information sufficient to evaluate their proposals based on the detailed factors listed above.
Offeror(s) cost/price proposal will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404.
PROVISIONS AND CLAUSES
It is anticipated that multiple firm fixed price type contracts will be awarded according to discipline. Any resultant contract shall include the clauses applicable to the selected offeror's organization and type of contract awarded as required by Public Law, Executive Order, or acquisition regulations in effect at the time of execution of the proposed contract.
The following Provisions and Clauses apply:
FAR 52.212-1 Instruction to Offerors-/Commercial Items (OCT 2015); FAR 52.212-2 Evaluation - Commercial Items (OCT 2014) (Additional Evaluation criteria set forth in the solicitation; FAR 212-3, Offeror Representations and Certifications - Commercial Items (NOV 2015); FAR 52.212-4 Contract Terms and Conditions Commercial Items (MAY 2015); FAR 52.212-5 Contract Terms and Conditions Required to Implement Statues or Executive-Commercial Items (JAN 2016); FAR 52.217-8 Option To Extend Services (NOV 1999); FAR 52.217-9 Option to Extend the Term of the Contract, (MAR 2000); FAR 219-6 Notice of Total Small Business Set-Aside (NOV 2011); FAR 52.222-3 Convict Labor (JUN 2003); FAR 52.223-6 Drug Free Workplace (May 2001); FAR 52.227-14 Rights In Data - General (MAY 2014), FAR 52.228-5 Insurance - Working On a Government Installation (JAN 1997); and FAR 52.232-33 Payment by Electronic Funds Transfer - System for Award Management (JULY 2013).
The Contractor shall comply with the following clauses, which are incorporated in this contract in full text, to implement provisions of law or Executive orders applicable to acquisitions of commercial items.
52.217-5 Evaluation of Options (JULY 1990)
Except when it is determined in accordance with FAR 17.206(b) not to be in the Government's best interests, the Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. Evaluation of options will not obligate the Government to exercise the option(s).(End of clause)52.217-6 Option for Increased Quantity (MAR 1998)The Government may increase the quantity of supplies called for in the Schedule at the unit price specified. The Contracting Officer may exercise the option by written notice to the Contractor within the current period of performance. Delivery of the added items shall continue at the same rate as the like items called for under the contract, unless the parties otherwise agree. (End of clause)52.217-8 Option to Extend Services, (NOV 1999)
The Government may require continued performance of any services within the limits and at the rates specified in the contract. These rates may be adjusted only as a result of revisions to prevailing labor rates provided by the Secretary of Labor. The option provision may be exercised more than once, but the total extension of performance hereunder shall not exceed 6 months. The Contracting Officer may exercise the option by written notice to the Contractor within 60 days from the expiration of the contract. (End of clause) 52.217-9 Option to Extend the Term of the Contract, (MAR 2000)
(a) The Government may extend the term of this contract by written notice to the Contractor within the current period of performance; provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least 30 days before the contract expires. The preliminary notice does not commit the Government to an extension. (b) If the Government exercises this option, the extended contract shall be considered to include this option clause. (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 60 months. (End of clause)
FAR 52.222.17 Non-displacement of Qualified Workers (May 2014)
The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract in full text, to implement provisions of law or Executive orders applicable to acquisitions of commercial items. (End of clause)
FAR 52.227-14 - Rights in Data - General (May 2014)
Information Security is Applicable to this requirement and the following information is required for RFP preparedness.
1. SECURITY CATEGORIZATION OF FEDERAL INFORMATION AND INFORMATION SYSTEMS (FIPS 199 Assessment)
a. Information Type:
[ ] Administrative, Management and Support Information:
[ x ] Mission Based Information:
b. Security Categories and Levels (SCL)
Confidentiality Level: [ ] Low [x ] Moderate [ ] HighIntegrity Level: [ ] Low [x ] Moderate [ ] HighAvailability Level: [ ] Low [x ] Moderate [ ] High
Overall Level: [ ] Low [ x ] Moderate [ ] High
This contract will entail the following position sensitivity levels:
[ ] Level 6: Public Trust - High Risk. Contractor/subcontractor employees assigned to Level 6 positions shall undergo a Suitability Determination and Background Investigation (MBI).
[ ] Level 5: Public Trust - Moderate Risk. Contractor/subcontractor employees assigned to Level 5 positions with no previous investigation and approval shall undergo a Suitability Determination and a Minimum Background Investigation (MBI), or a Limited Background Investigation (LBI).
[x ] Level 1: Non-Sensitive. Contractor/subcontractor employees assigned to Level 1 positions shall undergo a Suitability Determination and National Check and Inquiry Investigation (NACI).
Prospective Offeror Non-Disclosure Agreement[ x] Offerors WILL NOT require access to sensitive information in order to prepare an offer.[ ] Offerors WILL require access to sensitive information in order to prepare an offer.[ x] Systems Security Plan (SSP) is NOT required.
SOLICITATION - STATEMENT OF WORK/REPORTS/DELIVERABLE PROVISIONS
1 ROSTER OF EMPLOYEES REQUIRING SUITABILITY INVESTIGATIONS
The Contractor shall submit a roster, by name, position, e-mail address, phone number and responsibility, of all staff (including subcontractor staff) working under the contract that will develop, have the ability to access, or host and/or maintain a Federalinformation system(s). The roster shall be submitted to the Contracting Officer'sRepresentative (COR), with a copy to the Contracting Officer, within 14 calendar days of the effective date of the contract.
1 REPORTING OF NEW AND DEPARTING EMPLOYEES
The Contractor shall notify the Contracting Officer's Representative (COR) and Contracting Officer within five working days of staffing changes for positions that require suitability determinations as follows:
1 CONTRACTOR - EMPLOYEE NON-DISCLOSURE AGREEMENT(s)
The contractor shall complete and submit a signed and witnessed "Commitment to Protect Non-Public Information - Contractor Agreement" form for each contractor and subcontractor employee who may have access to non-public Department information under this contract. This form is located at:https://ocio.nih.gov/aboutus/publicinfosecurity/acquisition/Documents/Nondisclosure.pdf
SOLICITATION - SPECIAL CONTRACT REQUIREMENTS PROVISIONS
1 STANDARD FOR ENCRYPTION LANGUAGE, HHSAR 352.239-71, (January 2010) The Contractor shall use Federal Information processing Standard (FIPS) 140-2- compliant encryption (Security) Requirements for Cryptographic Module, as amended) to protect all instances of HHS sensitive information during storage and transmission. (Note: The Government has determined that HHS information under this contract is considered "sensitive" in accordance with FIPS 199, Standards for Security Categorization of Federal Information and Information Systems, dated February 2004).
1 SECURITY REQUIREMENT FOR FEDERAL INFORMATION TECHNOLOGY RESOURCES, HHSAR 352.239-72, (January 2010)
Applicability. This clause applies whether the entire contract or order (hereafter "contract"), or portion thereof, includes information technology resources or services in which the Contractor has physical or logical (electronic) access to, or operates a Department of Health and Human Services (HHS) system containing, information that directly supports HHS' mission. The term "information technology (IT)", as used in this clause, includes computers, ancillary equipment (including imaging peripherals, input, output, and storage devices necessary for security and surveillance), peripheral equipment designed to be controlled by the central processing unit of a computer, software, firmware and similar procedures, services (including support services) and related resources. This clause does not apply to national security systems as defined in FISMA.
1 INFORMATION SECURITY TRAINING
In addition to any training covered under paragraph (e) of HHSAR 352.239-72, the contractor shall comply with the below training:
1 PERSONNEL SECURITY RESPONSIBILITIES
In addition to any personnel security responsibilities covered under HHSAR 52.239-72, the contractor shall comply with the below personnel security responsibilities:
1 LOSS AND/OR DISCLOSURE OF PERSONALLY IDENTIFIABLE INFORMATION (PII) - NOTIFICATION OF DATA BREACH
The Contractor shall report all suspected or confirmed incidents involving the loss and/or disclosure of PII in electronic or physical form. Notification shall be made to the NIH Incident Response Team (IRT) via email (IRT@mail.nih.gov ) within one hour of discovering the incident. The Contractor shall follow up with IRT by completing and submitting one of the applicable two forms below within three (3) work days of incident discovery:
Consultants who contribute to the creation of new intellectual property will be named as inventors according to US or prevailing patent law. Accordingly, consultants must complete negotiations with the principal investigator's institution regarding assignment of rights and royalties distribution prior to advising on any activities. The consultant shall provide copies of all intellectual property agreements to the NIH COR, for documentation purposes.
CONFIDENTIAL TREATMENT OF SENSITIVE INFORMATION
The Contractor shall guarantee strict confidentiality of the information/data that it is provided by the Government or by persons or entities applying to or accepted to the Blueprint Neurotherapeutics Network during the performance of the contract. The Government has determined that the information/data that the Contractor will be provided during the performance of the contract is of a sensitive nature.
Disclosure of the information/data, in whole or in part, by the Contractor can only be made after the Contractor receives prior written approval from the Contracting Officer. Whenever the Contractor is uncertain with regard to the proper handling of information/data under the contract, the Contractor shall obtain a written determination from the Contracting Officer.
Contractor agrees that it will not use the Confidential Information for any purpose except as set forth within this SOW, unless such time as such Confidential Information becomes public information through the efforts of participants in the Blueprint Neurotherapeutics Network.
NOTICE OF SMALL BUSINESS SET-ASIDE
General. Offerors are solicited only from small business concerns. The procurement is to be awarded only to one or more such concerns, organizations, or individuals. This action is based on a determination by the Contracting Officer, alone or in conjunction with a representative of the Small Business Administration, that it is in the interest of maintaining or mobilizing the Nation's full productive capacity, or in the interest of war or national defense programs, or in the interest of assuring that a fair proportion of Government procurement is placed with small business concerns. Bids or proposals received from others will be considered non-responsive.
Definitions. The term "small business concern" means a concern, including its affiliates, which is independently owned and operated, is not dominant in the field of operation in which it is bidding on Government contracts, and can further qualify under the size standards in this solicitation. In addition to meeting these criteria, a small business concern submitting an offer in his own name shall furnish, in the performing the contract, only end items manufactured or produced by small business concerns in the United States or its outlying areas, provided that this additional requirement does not apply in connection with construction or service contracts.
COMMITMENT OF PUBLIC FUNDS
The Contracting Officer is the only individual who can legally commit the Government to the expenditure of public funds in connection with the proposed procurement. Any other commitment, either explicit or implied, is invalid.
Travel Costs - Commercial
Costs for lodging, meals, and incidental expenses incurred by Contractor personnel shall be considered to be reasonable and allowable to the extent they do not exceed on a daily basis the per diem rates set forth in the Federal Travel Regulations, General Services Administration (GSA). Therefore, if travel costs are applicable and proposed by offerors, please be advised that they shall be calculated using the per diem rate schedule as established by GSA. Reimbursement of travel costs under any contract awarded from this RFP shall be in accordance with FAR 31.205-46.
One copy of the offeror's (and any proposed subcontractor's) written travel policy shall be included in the business proposal. If an offeror (or any proposed subcontractor) does not have a written travel policy, the offeror shall so state.ON-SITE CONTRACTOR ACCESS TO GOVERNMENT PROPERTYThe Contractor shall be held responsible for Government Property, regardless of dollar value, when: 1. The contract requires contractor personnel to be located on a Government site or installation;2. The property utilized by contractor personnel is incidental to the place of performance; and,3. The property used by the contractor remains accountable to the Government
Responsibility includes physical presence, proper use and handling, normal maintenance, and reporting loss, damage or destruction.
Responsibility for government property shared by two or more contractors or located in space shared by two or more contractors shall be determined and documented by the contractors involved. In cases where the parties cannot reach agreement on shared responsibility, the matter will be referred to the NIH Property Officer for resolution.
POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE
a. Contractor Performance Evaluations
Interim and Final evaluations of Contractor performance will be prepared on this contract in accordance with FAR Subpart 42.15. The Final performance evaluation will be prepared at the time of completion of work. In addition to the Final evaluation, Interim evaluation(s) will be prepared Annually as follows on June 1st.
Interim and Final evaluations will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer, whose decision will be final.
Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.
b. Electronic Access to Contractor Performance Evaluations
Contractors may access evaluations through a secure Web site for review and comment at the following address:
CONTRACTING OFFICER REPRESENTATIVE
The following Contracting Officer's Representative (COR) will represent the Government for the purpose of this contract:To be specified prior to award
The COR is responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) interpreting the statement of work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the resolution of technical problems encountered during performance.
The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; (5) otherwise change any terms and conditions of this contract; or (6) sign written licensing agreements. Any signed agreement shall be incorporated by reference in Section K of the contract
The Government may unilaterally change its COR designation.
COMMUNICATIONS PRIOR TO CONTRACT AWARD
Offerors shall direct all communications to the attention of the Contract Specialist cited herein. Communications with officials outside of the contracting office may compromise the competitiveness of this acquisition and result in cancellation of the requirement.
Interested Offerors may submit quotations electronically to this notice no later than 8:00 AM. (EST) May 15, 2016. Questions regarding this solicitation must be received in writing by this office no later than May 1, 2016. Responses to questions will be answered in an amendment to this posting. Offerors must submit a completed FAR 52.212-3. The quotation shall include fully-burdened hourly wage rates for the key personnel assigned to this requirement. The Government intends to make multiple awards based upon best value to the Government, technical and price factors considered.
The anticipated award date for this requirement shall be on or before June 1, 2016. Facsimile submissions are not authorized and collect calls will not be accepted. Submit offers to Andriani Buck at the address listed herein. Please reference the solicitation number HHS-NIH-NIDA-SSSA-RFP-16-46 on your offer. Requests for information concerning this requirement are to be addressed to Andriani Buck via e-mail to email@example.com prior to the date stated above.